Biotech drug developer Repligen Corp. said Sept. 10 ImClone Systems Inc. has agreed to pay $65 million to Repligen and co-plaintiff Massachusetts Institute of Technology as part of a patent infringement case settlement.

The case began in May 2004, when Repligen and MIT filed a patent infringement suit against ImClone related to the manufacture and sale of the drug Erbitux. The patent in question is held by MIT and exclusively licensed to Repligen.